Hannah Clarke

As the year comes to a close, we revisit some of this year’s top content on prostate cancer.

As the year comes to a close, we revisit some of this year’s top content on bladder cancer.

The study is set to begin in January 2024.

"This study, using a novel technology to manage hot flashes, truly moves the field forward in improving the quality of life for men with prostate cancer,” says Alicia K. Morgans, MD, MPH.

"If the diversity and robust functional potential of the healthy human microbiome is repeatedly assaulted by the average Westernized lifestyle via antibiotic exposure, diet, and other environmental factors, kidney stone prevalence will continue to increase," the authors write.

A response by the FDA is expected by February 2024.

Overall, 177Lu-PNT2002 demonstrated a median radiographic progression-free survival of 9.5 months, compared with 6.0 months among patients who were treated with an ARPI.

The BLA submission is supported by findings from the phase 3 ZIRCON study, which demonstrated high specificity and sensitivity of the agent for PET/CT imaging of ccRCC.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

The approval is supported by findings from the phase 3 EV-302 trial, which showed that the combination led to significant improvements in overall survival and progression-free survival compared with chemotherapy.

The approval is supported by findings from the phase 3 LITESPARK-005 trial.

All of those enrolled in the study have been implanted for at least 7 months, with the longest implantation at 15 months.

All patients had prostates greater than 80 mL and had not responded to prior medication therapy.

Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation.

The median number of harms criteria reported in RCTs in urology increased from 5.3 in 2012 to 7.2 in 2020.

“We found that these genetic proxies of thiazide diuretics were associated with a 15% lower risk of kidney stones,” says Jefferson Triozzi, MD.

"Our studies consistently demonstrated that data from the Decipher Prostate Genomic Classifier was more reliably predictive of prostate cancer progression and underlying pathology than any other clinical data available, including MRI," says Eric Kim, MD.

“The impressive duration of response, still expanding with 6/8 responses ongoing, is indicative of restoration of a lasting immunologic tumor control in advanced solid tumor patients,” says Eugen Leo, MD, PhD, MBA

"In these studies, we were pleased to find that disitamab vedotin has consistent efficacy and manageable safety in patients with chemotherapy-refractory mUC," says Jun Guo, MD.

According to Neuspera, results from phase 2 of the SANS-UUI trial are expected to support an application for FDA approval of the device in patients with OAB-related UUI.

"I'm thrilled to continue my partnership with SMPA to educate and empower others to address their OAB," says Holly Robinson Peete.

The patents apply exclusively to the Ga-68 HBED-PSMA-11 production kit (Locametz), developed by Advance Accelerator Applications.

“The study highlights the importance of considering how altering cell metabolism could impact prostate cancer and its response to treatment," says Jenna Giafaglione.

According to Clarity Pharmaceuticals, the final results are intended to support an application to the FDA for approval of 64Cu-SAR-bisPSMA for imaging in patients with prostate cancer.

Overall, Black men were 24% less likely to receive or be prescribed a novel hormonal therapy agent compared with White men.

Taher Naeem, a fourth-year medical student at Baylor College of Medicine, highlights 3 abstracts that were presented during the 24th Annual Fall Scientific Meeting of the SMSNA in San Diego, California.

The Bladder EpiCheck test received FDA 510(k) clearance in May 2023 for use in patients with NMIBC.

The data showed that Black, Hispanic, and uninsured patients were independently associated with a lower likelihood of receiving immunotherapy.

No dose-limiting toxicities were observed among the initial 3 patients in cohort 3, and no patients experienced adverse events related to 64Cu-SAR-bisPSMA.

The investigators observed no dose limiting toxicities or serious adverse events among all patients who received an ARX517 dose of 3.4 mg/kg, the highest dose tested in the trial.